(Q35805896)

10 August 2017

title

New antipsychotics, compliance, quality of life, and subjective tolerability--are patients better off? (English)

1 reference

10 August 2017

A George Awad

1

1 reference

10 August 2017

Lakshmi N P Voruganti

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Canadian Journal of Psychiatry

10 August 2017

published in

1 reference

10 August 2017

volume

49

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

297-302

1 reference

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Novel antipsychotics and severe hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Determinants of medication compliance in schizophrenia: empirical and clinical findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Treatment Adherence Associated With Conventional and Atypical Antipsychotics in a Large State Medicaid Program

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Predictors of Risk of Nonadherence in Outpatients With Schizophrenia and Other Psychotic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Measuring quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Convergent validation of quality of life assessments for persons with severe mental illnesses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

A clinical evaluation of risperidone in the treatment of schizophrenia: a 10-week, open-label, multicenter trial. ARCS Study Group. Assessment of Risperdal in a Clinical Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Benefits of switching from typical to atypical antipsychotic medications: a longitudinal study in a community-based setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Quality of life and new antipsychotics in schizophrenia. Are patients better off?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Subjective response to antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Neuroleptic dysphoria: towards a new synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Quality of life in schizophrenia: insight and subjective response to neuroleptics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Short report: comparison of patient satisfaction and burden of adverse effects with novel and conventional neuroleptics: a naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Which neuroleptic would psychiatrists take for themselves or their relatives?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F070674370404900504

10.1177/070674370404900504

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference